ClinicalTrials.gg

Program

NVX-COV2705

Its studies are mostly in COVID-19, led by 2 companies.

Furthest: phase 4, since Jul 17, 20252 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novavax10 open or runningphase 4since Jul 17, 2025Jul 17, 2025none ahead
Sanofi10 open or runningphase 3since Jul 14, 2025Jul 14, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 14, 2025First study: phase 3 study in COVID-19New to SanofiSanofi · NCT07079670 · 676 enrolled · United States
  2. Jul 17, 2025Novavax’s first study: phase 4 study in COVID-19New to NovavaxNovavax · NCT07086222 · 6,500 enrolled · United States
  3. Oct 23, 2026Phase 4 study terminatedStudy stoppedNCT07086222 · “The study was terminated early due to low COVID-19 incidence and high population immunity, limiting meaningful vaccine efficacy assessmen…”

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07086222COVID-19 · United States4TerminatedNovavaxOct 9, 20266,500
NCT07079670COVID-19 · United States3CompletedSanofiJan 12, 2026676

How it is read

Names in the registry

  • “NVX-CoV2705”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.